I. RESTATEMENT (Details 1) - USD ($)	3 Months Ended		9 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Research and development expenses	$ 3,180,401	$ 4,361,509	$ 13,307,275	$ 13,206,400
Total operating expenses	4,776,108	6,036,123	17,655,105	17,193,411
Operating loss	(4,758,719)	(5,906,148)	(17,603,283)	(17,009,685)
Interest income (expense), net	(495,709)	(464,202)	(1,436,095)	(1,412,691)
Net Loss	$ (4,464,063)	$ (3,861,606)	$ (9,369,401)	$ (10,384,402)
Net income per share - basic			$ (1.29)	$ (2.21)
Net income per share - diluted			$ (1.34)	(2.21)
Net income per share - basic and diluted	$ (0.53)	$ (0.78)		$ (2.21)
Previously Reported
Research and development expenses	$ 3,657,000	$ 4,838,108	$ 14,737,073	$ 14,636,197
Total operating expenses	5,252,707	6,512,722	19,084,903	18,623,208
Operating loss	(5,235,318)	(6,382,747)	(19,033,081)	(18,439,482)
Interest income (expense), net	(755)	24,679	44,709	49,142
Net Loss	$ (4,445,708)	$ (3,849,324)	$ (9,318,395)	$ (10,352,366)
Net income per share - basic			$ (1.29)	$ (2.20)
Net income per share - diluted			$ (1.33)	$ (2.20)
Net income per share - basic and diluted	$ (0.53)	$ (0.78)
Adjustment
Research and development expenses	$ (476,599)	$ (476,599)	$ (1,429,798)	$ (1,429,797)
Total operating expenses	(476,599)	(476,599)	(1,429,798)	(1,429,797)
Operating loss	476,599	476,599	1,429,798	1,429,797
Interest income (expense), net	(494,954)	(488,881)	(1,480,804)	(1,461,833)
Net Loss	$ (18,355)	$ (12,282)	$ (51,006)	$ (32,036)